Comparing Daptomycin and Vancomycin for MRSA Bloodstream Infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is an open-label randomized controlled trial that aims to compare the effectiveness of two commonly used antibiotics, daptomycin and vancomycin, in treating patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. Participants will be randomly assigned to receive either daptomycin or vancomycin, and their outcomes will be monitored to determine which treatment is more effective. The study is part of a larger adaptive platform trial focused on improving treatment for Staphylococcus aureus infections.

Why it matters

Who can join: the full rules

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion Criteria:

* Methicillin-resistant S. aureus bacteremia

Exclusion Criteria:

* Severe allergy or non-severe rash to vancomycin or daptomycin
* Suspected or confirmed MRSA pneumonia
* Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Where it's running

• Blacktown Hospital
  Blacktown, New South Wales, Australia Recruiting
• Concord Repatriation and General Hospital
  Concord, New South Wales, Australia Recruiting
• John Hunter Hospital
  Newcastle, New South Wales, Australia Recruiting
• Westmead Hospital
  Westmead, New South Wales, Australia Recruiting
• Royal Brisbane and Women's Hospital
  Herston, Queensland, Australia Recruiting
• Flinders Medical Centre
  Bedford Park, South Australia, Australia Recruiting

Study contacts

• Principal investigator: Todd C Lee, MD MPH FIDSA — McGill University Health Centre/Research Institute of the McGill University Health Centre
• Study coordinator: Lina Petrella
• Email: lina.petrella@muhc.mcgill.ca
• Phone: 514-934-1934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to dabigatran versus staying on apixaban/edoxaban/rivaroxaban for S. aureus bloodstream infection

  This trial will try whether switching people with S. aureus bloodstream infection who are already taking apixaban, edoxaban, or rivaroxaban to dabigatran leads to better outcomes.

  Recruiting at 3 sites Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · St. John's, Newfoundland and Labrador and 2 other locations · NCT06650501

• Combining two antibiotics to treat Staphylococcus aureus bacteremia

  This study is testing if using two antibiotics together can help adults with Staphylococcus aureus bacteremia get better faster than the usual treatment.

  Recruiting at 8 sites Phase 2 McGill University Health Centre/Research Institute of the McGill University Health Centre · Calgary, Alberta and 7 other locations · NCT04886284

• Clopidogrel versus aspirin to lower cardiovascular and infection complications in people with Staphylococcus aureus bloodstream infection

  This will try switching people with Staphylococcus aureus bloodstream infection who are already taking aspirin for heart protection to clopidogrel to see if it improves infection outcomes.

  Recruiting at 3 sites Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · St. John's, Newfoundland and Labrador and 2 other locations · NCT06650488

• Combination Antibiotics for Staphylococcus aureus Bacteremia in adults

  This study tests whether using two antibiotics together for adults with Staphylococcus aureus in the blood works better than a single antibiotic.

  Recruiting at 13 sites Phase 4 Intermountain Health Care, Inc. · Brighton, Colorado and 12 other locations · NCT07376889

• Evaluating treatments for Staphylococcus aureus bloodstream infections

  This study is testing different treatments for people with Staphylococcus aureus bloodstream infections to find out which ones work best to help them recover and live longer.

  Recruiting at 126 sites Phase 4 University of Melbourne · Houston, Texas and 160 other locations · NCT05137119

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.